EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer

Raisa Ghosh iD, Sungyoung Auh iD, Sriram Gubbi iD, Padmasree Veeraraghavan, Craig Cochran, Leila Shobab iD, Mark L Urken, Kenneth D Burman iD, Leonard Wartofsky iD, Joanna Klubo-Gwiezdzinska iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae537 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Raisa Ghosh und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20814, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroxine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural Research Program of the National Institutes of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Supraphysiologic T4 doses are used in intermediate- and high-risk patients with differentiated thyroid cancer (IR/HR-DTC) to suppress tumor progression by TSH. However, preclinical data suggest that T4 can also act as a growth stimulus for cancer, but there is no clinical evidence supporting this claim.

Objective

We analyzed the association between free T4 (FT4) and progression-free survival (PFS) in patients with IR/HR-DTC.

Methods

This longitudinal cohort study, approved by multi-institutional review board, included patients with IR/HR-DTC treated uniformly with total thyroidectomy, radioiodine, and TSH suppression therapy, with at least 3 TSH and FT4 values available. Association between FT4 and PFS at landmarks 6, 12, and 18 months was assessed by Kaplan-Meier survival curves, whereas competing risks were assessed through Cox proportional hazards model.

Results

From 739 screened patients, 382 met the inclusion criteria and were characterized by a median age of 46 (34-59) years, 64.1% women, and treated with a median radioiodine dosage of 159 (110-410) mCi. During follow up of 7.1 (3.4-12.7) years, 34.6% experienced disease progression. Elevated FT4, observed in 29.3% of patients, was not associated with worse PFS (hazard ratio [HR], 0.9; CI, 0.54-1.5; P = .69), whereas age (HR, 1.02; CI, 1.004-1.04; P = .01), tumor size (HR, 1.15; CI, 1.04-1.28; P = .01) and metastases to the lateral neck lymph nodes (HR, 2.9; CI, 1.7-4.74; P < .001), bones (HR, 4.87; CI, 1.79-13.3; P = .002), and brain (HR, 5.56; CI; 2.54-12.2; P < .001) were associated with shorter PFS.

Conclusion

Contrary to preclinical evidence, elevated FT4 levels do not affect PFS in patients with IR/HR-DTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroxineAdultFemaleHumansMaleMiddle AgedFollow-Up StudiesIodine RadioisotopesLongitudinal StudiesPrognosisProgression-Free SurvivalThyroidectomy

Stichwörter der Autor:innen

progression-free survivalthyroid cancerthyrotropin suppressionthyroxine

Substanzen

Iodine RadioisotopesThyroxine

Autor:innen und Institutionen

  • National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20814, USA.
  • Department of Endocrinology, MedStar Washington Hospital Center, Washington, DC, USA.
  • Institute of Head, Neck and Thyroid Cancer, Mount Sinai Beth Israel Medical Center, New York, NY 10003, USA.

ORCID-Profile: Raisa Ghosh, Sungyoung Auh, Sriram Gubbi, Leila Shobab, Kenneth D Burman, Leonard Wartofsky, Joanna Klubo-Gwiezdzinska

Förderung

  • Intramural Research Program of the National Institutes of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ghosh, R., Auh, S., Gubbi, S., Veeraraghavan, P., Cochran, C., Shobab, L., Urken, M. L., Burman, K. D., Wartofsky, L., & Klubo-Gwiezdzinska, J. (2025). Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae537

Vancouver

Ghosh R, Auh S, Gubbi S, Veeraraghavan P, Cochran C, Shobab L, et al. Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae537

BibTeX
@article{Ghosh2025,
  author = {Ghosh, Raisa and Auh, Sungyoung and Gubbi, Sriram and Veeraraghavan, Padmasree and Cochran, Craig and Shobab, Leila and Urken, Mark L and Burman, Kenneth D and Wartofsky, Leonard and Klubo-Gwiezdzinska, Joanna},
  title = {Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae537}
}
Kostenlos starten →